Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velzatinib in Moderate or Severe Renal Impairment Compared to Healthy Participants
NCT07867171Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Primary completion
- Sep 2027
01
Overview
Phase 1, open-label trial of velzatinib in gastrointestinal neoplasms (3 arms), sponsored by GSK. Primary endpoints: Maximum observed plasma concentration up to 936 hours, Area under the concentration-time curve from time zero extrapolated to infinity up to 936 hours and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
velzatinib
03
Conditions
gastrointestinal neoplasms
Beyond the preview
Go deeper on NCT07867171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867171.